Vera Bril
Co-Applicant
Professor of Neurology at University of Toronto | Neurologist and Director of the Neuromuscular Section at University Health Network and the University of Toronto
Senior Scientist at the Toronto General Research Institute
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Biography
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She directs the Ellen & Martin Prossserman Centre for Neuromuscular Diseases at the University Health Network, and the Prosserman Family Neuromuscular Clinic and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy leading to publication of more than 350 journal articles.
Recent Publications
Bril, V, Drużdż, A, Grosskreutz, J, Habib, AA, Kaminski, HJ, Mantegazza, R et al.. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. 2025.272 (4)275 PMID:40105996
Habib, AA, Drużdż, A, Grosskreutz, J, Mantegazza, R, Sacconi, S, Utsugisawa, K et al.. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis. 2025. 22143602241308181 PMID:40034001
Bril, V, Drużdż, A, Grosskreutz, J, Habib, AA, Mantegazza, R, Sacconi, S et al.. Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis. 2025. 22143602241305511 PMID:40033991
Antozzi, C, Vu, T, Ramchandren, S, Nowak, RJ, Farmakidis, C, Bril, V et al.. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025.24 (2)105-116 PMID:39862879
Bril, V, Gilhus, NE. Aging and infectious diseases in myasthenia gravis. J Neurol Sci. 2025.468 123314 PMID:39671879
Idiaquez, JF, Barnett-Tapia, C, Perkins, BA, Bril, V. Assessing corneal dendritic cells in glucose dysregulation small-fibre neuropathy. J Peripher Nerv Syst. 2024.29 (4)400-405 PMID:39532698
Hanna, A, Ing, EB, Sundaram, AN, Bril, V, Sharma, RA. Late-Onset Mitochondrial Neurogastrointestinal Encephalopathy Presenting With Isolated Ophthalmic Findings. J Neuroophthalmol. 2024. PMID:39527508
Hadden, RDM, Andersen, H, Bril, V, Basta, I, Rejdak, K, Duff, K et al.. Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial. J Peripher Nerv Syst. 2024.29 (4)441-452 PMID:39523874
Bril, V, Berkowicz, T, Szczudlik, A, Nicolle, MW, Bednarik, J, Hon, P et al.. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. Muscle Nerve. 2025.71 (1)43-54 PMID:39506903
Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK et al.. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024.17 17562864241273036 PMID:39297052
See more on PubMed